Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial

BACKGROUND: This randomised phase II study evaluated the efficacy and safety of panitumumab added to docetaxel-based chemotherapy in advanced oesophagogastric cancer. METHODS: Patients with metastatic or locally recurrent cancer of the oesophagus, oesophagogastric junction or stomach received doceta...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Br J Cancer
Asıl Yazarlar: Tebbutt, Niall C, Price, Timothy J, Ferraro, Danielle A, Wong, Nicole, Veillard, Anne-Sophie, Hall, Merryn, Sjoquist, Katrin M, Pavlakis, Nick, Strickland, Andrew, Varma, Suresh C, Cooray, Prasad, Young, Rosemary, Underhill, Craig, Shannon, Jennifer A, Ganju, Vinod, Gebski, Val
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2016
Konular:
Clinical Study
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4782199/
https://ncbi.nlm.nih.gov/pubmed/26867157
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2015.440
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller